Welcome to our dedicated page for Abacus Life news (Ticker: ABL), a resource for investors and traders seeking the latest updates and insights on Abacus Life stock.
Abacus Life, Inc. (NASDAQ: ABL) is a vertically integrated alternative asset manager specializing in investing in life insurance products throughout the lifecycle of a life insurance policy. Established in 2004, the company has carved a niche in the life settlement market, having purchased life insurance policies with over $5 billion in face value. Abacus Life serves consumers seeking liquidity by actively managing these policies through trading, holding, or servicing.
Abacus Life stands out for its detailed, data-driven approach to actuarial technology, democratizing the life insurance space via three key channels: ABL Tech, ABL Wealth, and ABL Longevity Growth & Income Funds. ABL Tech focuses on leveraging AI and innovative technology to enhance data security and operational efficiency, while ABL Wealth and ABL Longevity Funds offer tailored wealth management and investment solutions.
The company has achieved significant milestones, such as its recent $15 million stock repurchase program and the appointment of notable industry experts to its leadership team. They lead the market in funds paid to clients, holding a 26% market share in 2023, paying over $220 million to policyholders.
Abacus Life’s financial stability is evident in its impressive revenue growth, with total revenues for Q1 2024 doubling to $21.5 million compared to the previous year. They also maintain strong relationships with 78 institutional partners and 30,000 financial advisors and are accredited by the BBB with an A+ rating.
With operations in 49 states, Abacus Life is committed to maintaining the confidentiality of personal information, complying with HIPAA and privacy laws. Their stock is publicly traded on the Nasdaq Exchange under the ticker symbol ABL.
For more detailed information, visit their website at www.Abacuslife.com.
Abacus Life (NASDAQ: ABL) reported Q3 2024 results with total revenue growing 33% year-over-year to $28.1 million. Despite posting a GAAP net loss of $5.1 million due to a non-cash warrant liability increase, the company achieved significant growth metrics with Adjusted Net Income up 65% to $14.9 million and Adjusted EBITDA rising 54% to $16.7 million. Policy originations increased 54% to 278, with capital deployment of $93.2 million. The company is advancing its ABL Tech platform with over 20 clients and progressing on acquisitions of Carlisle Management and FCF Advisors, expected to add $2.6 billion in assets under management.
Abacus Life (NASDAQ: ABL) has released preliminary Q3 2024 results, anticipating Total Revenue between $26.0 and $28.0 million, representing a 23-33% year-over-year growth. The company expects a GAAP Net Loss between $6.0 and $6.75 million, primarily due to a non-cash increase in warrant liability of $8.0 to $9.0 million. Adjusted EBITDA is projected between $14.0 and $16.0 million, showing a 30-48% year-over-year growth.
CEO Jay Jackson highlighted key acquisitions of Carlisle Management Company SCA and FCF Advisors, as well as the addition of new executives. The company also partnered with Lorisco to launch PREADISAN™, a health prediction and actuarial technology tool. Abacus will release full Q3 2024 financial results on November 7, 2024, followed by a conference call.
Abacus Life (NASDAQ: ABL), a leader in longevity and actuarial technology asset management, has appointed Robert F. Phillips as Senior Vice President, Investor Relations and Corporate Affairs. With over 30 years of experience in capital markets and investor relations, Phillips will lead Abacus Life's investor relations strategy and play a key role in advancing strategic business initiatives. Reporting directly to CEO Jay Jackson, Phillips will focus on strengthening engagement with investment and capital markets communities.
Phillips' extensive background includes roles as Senior Managing Director at Nasdaq, heading Investor Relations and Business Development for an SEC-registered investment advisor, and experience in institutional trading & brokerage. He holds a B.A. from Hamilton College and an M.B.A. in Finance from NYU Stern School of Business.
Abacus Life, Inc. (NASDAQ: ABL), a leading global alternative asset manager specializing in lifespan-based financial products, has announced a significant milestone for its Abacus Policy Value Calculator. The calculator, which recently launched its newest generation, has surpassed 150,000 individual submissions from insureds, representing more than $87 billion in face value.
CEO Jay Jackson emphasized the company's commitment to providing instant access to their valuation database through the calculator. This tool offers insureds a transparent and up-to-date estimate of their policy's value. The high volume of submissions has allowed Abacus to further refine its models and actuarial databases, enhancing the accuracy of its valuations.
Abacus Life (NASDAQ: ABL), a leading global alternative asset manager specializing in lifespan-based financial products, has announced the appointment of Corey McLaren as Managing Director, Capital Markets. Based in Boston, McLaren brings nearly two decades of financial services experience, including over 15 years in life settlements.
McLaren's previous roles include Director of Alternative Strategies at Spearhead Capital, where he managed their life settlement investment fund, and Director at FDO Partners, where he helped launch and source policies for three life settlement funds. Abacus CEO Jay Jackson expressed excitement about McLaren's expertise and its potential to drive the company's strategic vision forward.
Abacus Life (NASDAQ: ABL) and Lorisco Life have announced the launch of PREADISAN™, a cutting-edge health prediction platform that combines machine learning and modern proteomics. This partnership aims to revolutionize longevity-based health prediction and actuarial technology in the life settlements industry.
PREADISAN™ introduces a novel risk score that utilizes blood-based proteomic biomarker analysis and clinically driven AI models to assess mortality risks. This tool goes beyond traditional statistics-based life expectancy opinions, offering individualized insights for more personalized financial planning.
The partnership enables Abacus to enhance its leading capabilities in life settlements and actuarial technology, providing customized financial offerings based on Lorisco's health prediction platform. This collaboration is expected to significantly impact the future of financial planning and life settlements by focusing on longevity and health predictions.
Abacus Life (NASDAQ: ABL) reported strong Q2 2024 results, with total revenue doubling year-over-year to $29.1 million. The company's adjusted net income grew 75% to $11.8 million, while adjusted EBITDA increased 83% to $16.7 million. Abacus completed a public equity offering raising over $90 million, which was deployed towards new policy originations and growth initiatives. The company also announced two significant acquisitions: Carlisle Management and FCF Advisors, expected to add approximately $2.6 billion in assets under management. These moves align with Abacus' strategy to expand its global presence and diversify its product offerings in the longevity and actuarial technology space.
Abacus Life (NASDAQ: ABL) has announced a definitive agreement to acquire FCF Advisors, a New York-based asset manager specializing in free cash flow-focused investment strategies. This acquisition aligns with Abacus' expansion of ABL Wealth and will add up to $600 million in assets under management to the company. FCF Advisors is known for its free cash flow analytics and research, offering over 50 customizable free cash flow index strategies across 8 global equities allocation categories.
The deal is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This strategic move aims to enhance Abacus Life's ability to provide comprehensive, lifespan-based financial advisory services and products, furthering its goal of delivering holistic and tailored financial solutions to clients throughout their lives.
Abacus Life (NASDAQ: ABL) has released preliminary Q2 2024 results, showing strong growth. The company expects:
- Total Revenue between $28.0-$30.0 million (146-163% YoY growth)
- Net Income between $0.0-$1.0 million
- Adjusted EBITDA between $15.0-$17.0 million (64-86% YoY growth)
CEO Jay Jackson highlighted key achievements, including a successful public offering raising over $90 million and a new distribution partnership with AIMCOR. Abacus also announced an agreement to acquire Carlisle Management Company SCA. The company will release full Q2 2024 results on August 12, 2024.
Abacus Life (NASDAQ: ABL) has announced a definitive agreement to acquire Carlisle Management Company SCA, a Luxembourg-based investment manager in the life settlement space, for approximately $200 million. This strategic acquisition will add up to $2 billion in assets under management to Abacus, accelerating its expansion as a global alternative asset manager. The deal aligns with Abacus' goal of enhancing its offering to institutional investors seeking attractive risk-adjusted returns with low correlation to other asset classes.
Key points of the acquisition include:
- Carlisle shareholders will receive $73.5 million in Abacus bonds and 9.3 million Abacus common stock
- The transaction is subject to regulatory approval and certain performance thresholds
- Carlisle is licensed as an Alternative Investment Fund Manager under CSSF oversight in Luxembourg
- The acquisition is expected to provide synergies and expand Abacus' global financial presence
FAQ
What is the current stock price of Abacus Life (ABL)?
What is the market cap of Abacus Life (ABL)?
What does Abacus Life, Inc. specialize in?
What recent achievements has Abacus Life accomplished?
How is Abacus Life democratizing the life insurance space?
What are Abacus Life's financial highlights for Q1 2024?
Who are the recent key hires at Abacus Life?
What makes Abacus Life unique in the life settlement industry?
How does Abacus Life ensure the confidentiality of personal information?
Where is Abacus Life's stock traded?
What is Abacus Life's approach to technology and innovation?
What partnerships does Abacus Life have to enhance its distribution network?
